Size and PEG Length-Controlled PEGylated Monocrystalline Superparamagnetic Iron Oxide Nanocomposite for MRI Contrast Agent.

Objective: PEGylated superparamagnetic iron oxide (SPIO) is the most promising alternatives to gadolinium-based contrast agents (GBCAs) in MRI. This paper is to explore the imaging effects of PEGylated SPIO, which is influenced by particle sizes and surface polyethylene glycol (PEG) coating, using as MRI contrast agents at different magnetic field intensities.

Methods: Firstly, nine PEGylated monocrystalline SPIO nanoparticles with different nanocrystal sizes and different molecular weights PEG coating were prepared, and then physical and biological properties were analyzed.

Genetic Polymorphisms: A Novel Perspective on Acute Pancreatitis.

Acute pancreatitis (AP) is a complex disease that results in significant morbidity and mortality. For many decades, it has compelled researchers to explore the exact pathogenesis and the understanding of the pathogenesis of AP has progressed dramatically. Currently, premature trypsinogen activation and NF-B activation for inflammation are two remarkable hypotheses for the mechanism of AP.

Methane explosion suppression characteristics based on the NaHCO/red-mud composite powders with core-shell structure.

The NaHCO/red-mud (RM) composite powders were successfully prepared by the solvent-anti-solvent method for methane explosion suppression. The RM was used as a carrier, and the NaHCO was used as a loaded inhibitor. The NaHCO/RM composite powders showed a special core-shell structure and excellent endothermic performance.

Magnetic resonance imaging for pancreatic ductal adenocarcinomas induced by N-nitrosobis (2-oxopropyl) amine in Syrian golden hamsters.

Objectives: This study aimed to study magnetic resonance imaging (MRI) findings of pancreatic ductal adenocarcinomas (PDAs) induced by N-nitrosobis (2-oxopropyl) amine (BOP) in Syrian hamsters.

Methods: A total of 101 female hamsters, 8 weeks old, were randomized into 3 groups. They were randomized into a BOP-treated group (n = 80; with weekly subcutaneous injections of BOP [10 mg/kg body weight] for 7 consecutive weeks), a saline-treated group (n = 16), and an untreated group (n = 5).

[PPARdelta + 294T/C gene polymorphism related to plasma lipid, obesity and left ventricular hypertrophy in subjects with metabolic syndrome].

Objective: To investigate the relationship between PPARdelta + 294T/C gene polymorphism and lipid profile, obesity and left ventricular hypertrophy (LVH) in patients with metabolic syndrome (MS).

Methods: This study was conducted in 300 patients with MS and 174 patients with essential hypertension (EH) and 143 patients with type 2 diabetes mellitus (T2DM). MS was diagnosed according to 1999 WHO criteria.

[Peroxisome proliferator-activated receptor gamma C-161T polymorphism and carotid artery atherosclerosis in metabolic syndrome].

Objective: To assess the relationship between PPAR gamma C161-T polymorphism and Carotid Atherosclerosis in metabolic Syndrome (MS).

Methods: Polymerase chain reaction-restricted fragments length polymorphism was used to study the distribution of the PPAR gamma C161-T polymorphism in 248 metabolism syndrome, 163 essential hypertension (EH) and 115 type 2 diabetes mellitus (DM) patients and 121 normal controls. Fasting insulin (FINS), fasting blood glucose (FBG), uric Acid (UA), plasma lipids and ultrasonography for carotid artery were examined.